Neurological Biomarkers Market Report Examines Leading Companies And Growth Opportunities

The neurological biomarkers market is on a trajectory of significant expansion, driven by advancements in personalized medicine and innovative diagnostic technologies. This sector is gaining attention for its potential to transform the way neurological disorders are detected and managed, offering promising opportunities for healthcare providers and patients alike.

Forecasted Growth and Valuation in the Neurological Biomarkers Market
The market for neurological biomarkers is projected to experience rapid growth, reaching an estimated value of $22.82 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 14.0%. Several factors contribute to this surge, including the increasing adoption of biomarker-based personalized therapies, growing demand for metabolomics biomarkers, heightened investment in central nervous system (CNS) drug development, the emergence of next-generation diagnostic tools, and expanding use of biomarkers to monitor disease progression. Key trends anticipated during this period include a rise in early neurological diagnosis through biomarkers, broader use of proteomic and genomic biomarkers, expanded application of imaging biomarkers in CNS disorder assessment, increased incorporation of biomarkers into drug development processes, and a stronger clinical emphasis on testing biomarkers for neurodegenerative diseases.

The neurological biomarkers market size has grown rapidly in recent years. It will grow from $11.92 billion in 2025 to $13.52 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to rising prevalence of neurological disorders, early development of protein biomarkers, increased use of imaging biomarkers, growing adoption of dna biomarkers, initial integration of biomarkers in clinical trials.

Download a free sample of the neurological biomarkers market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Primary Industry Players Leading the Neurological Biomarkers Market
The neurological biomarkers sector includes several prominent companies that play a vital role in shaping the market landscape. These leading enterprises include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton dic*kinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, and Acumen Pharmaceuticals.

Strategic Moves Enhancing Market Position
In April 2024, GE HealthCare, a medical technology company based in the United States, acquired MIM Software Inc. for an undisclosed sum. This acquisition aims to boost precision care through the integration of advanced imaging analytics and workflow optimization, ultimately improving outcomes for patients and efficiency for healthcare providers. MIM Software Inc. specializes in advanced medical imaging solutions, which are expected to enhance the detection and analysis of neurological biomarkers, reinforcing GE HealthCare's capabilities in delivering personalized treatment across various medical fields.

View the full neurological biomarkers market report:
https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Innovations and Product Developments in Neurological Biomarkers
Companies in this market are actively developing novel biomarker blood tests to strengthen their competitive advantage. Such tests analyze specific molecules or indicators in blood to provide insight into biological conditions or neurological diseases. For example, in July 2023, Quanterix Corporation, a US-based firm known for ultra-sensitive digital immunoassay technology, launched the LucentAD biomarker blood test. This test is designed to assist clinicians in assessing patients with cognitive symptoms that suggest early signs of Alzheimer's disease. It measures p-Tau 181 levels, a recognized biomarker related to Alzheimer's pathology. While the LucentAD test supports diagnostic evaluation alongside other clinical tools, it is not intended as a standalone screening or diagnostic method.

Detailed Segmentation of the Neurological Biomarkers Market
This report segments the neurological biomarkers market into various categories to provide comprehensive insights:
1) By Product Type: Proteomics Biomarkers, Genomics Biomarkers, Metabolomics Biomarkers, Imaging Biomarkers, and Other Products
2) By Application: Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Schizophrenia, Depression, Multiple Sclerosis, and Spinal Muscular Atrophy
3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, and Other End-Users.

Further breakdown includes:
- Proteomics Biomarkers: Protein Biomarkers, Antibody Biomarkers
- Genomics Biomarkers: DNA Biomarkers, RNA Biomarkers
- Metabolomics Biomarkers: Metabolite Biomarkers, Lipid Biomarkers
- Imaging Biomarkers: MRI Biomarkers, PET Scan Biomarkers
- Other Products: Neuroinflammatory Biomarkers, Neurotransmitter Biomarkers

This detailed segmentation highlights the diverse and expanding nature of the neurological biomarkers market as it continues to evolve in response to technological advancements and growing clinical needs.

What's new in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.